Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–19 of 19 results
Advanced filters: Author: Arthur Kavanaugh Clear advanced filters

  • Treatment for inflammatory disorders has progressed remarkably since the introduction of highly effective biologic agents. Lessons can be learned from how other clinical specialties use immunomodulatory agents. In this article, Her and Kavanaugh introduce a rheumatology perspective to the management of inflammatory disorders to provide insights that might inform clinical practice in gastroenterology.

    • Minyoung Her
    • Arthur Kavanaugh
    Reviews
    Nature Reviews Gastroenterology & Hepatology
    Volume: 12, P: 363-368

  • Comorbidities affect outcomes and treatment decisions in patients with immune-driven systemic inflammatory disorders. New recommendations for the management of comorbidities in rheumatoid arthritis, psoriasis and psoriatic arthritis might help optimize the management of these diseases and improve patient outcomes, but several considerations are relevant to their clinical implementation.

    • Tristan Boyd
    • Arthur Kavanaugh
    News & Views
    Nature Reviews Rheumatology
    Volume: 11, P: 689-691

  • Treatment guidelines are an increasingly prominent topic of discussion in medicine. Can rheumatologists avoid the 'fatal flaw' inherent in attempts to standardize treatment decision-making—in which overly strict adherence to guidelines might be pursued at the expense of optimizing individual patients' outcomes?

    • Arthur Kavanaugh
    News & Views
    Nature Reviews Rheumatology
    Volume: 6, P: 505-506

  • In the double-blind, placebo-controlled phase 2 ARGO trial, patients with active psoriatic arthritis treated with a nanobody targeting IL-17A and IL-17F showed substantially better disease response rates compared with those receiving placebo treatment.

    • Iain B. McInnes
    • Laura C. Coates
    • Joseph F. Merola
    ResearchOpen Access
    Nature Medicine
    Volume: 31, P: 4160-4171

  • TNF inhibition is associated with an increased risk of lymphoma development. But is this association due to the TNF inhibitors themselves or the patient's underlying disease?

    • Arthur Kavanaugh
    News & Views
    Nature Reviews Rheumatology
    Volume: 13, P: 697-698

  • Tumor necrosis factor (TNF) inhibitors have proven highly effective in improving the signs and symptoms of rheumatoid arthritis, in inhibiting the progression of joint damage, and improving patients' quality of life. This Viewpoint will discuss the major concern relating to the actual use of TNF inhibitors in the clinic: their relatively high acquisition costs.

    • Arthur Kavanaugh
    Reviews
    Nature Clinical Practice Rheumatology
    Volume: 2, P: 346-347

  • The choice of optimum second-line DMARDs for patients with rheumatoid arthritis is fraught with challenges. The implementation of evidence-based guidelines designed to inform clinicians' decisions requires careful consideration of several important issues.

    • Arthur Kavanaugh
    News & Views
    Nature Reviews Rheumatology
    Volume: 5, P: 423-424

  • Undoubtedly, biologic agents have altered the landscape of therapeutic options for patients with rheumatoid arthritis (RA). Nevertheless, the choice can be bewildering, especially as several different molecules and pathways are the targets of approved and developmental therapies in RA. The authors of this Review provide a guide to navigate the current options and to understand how the picture is likely to evolve in the near future.

    • Ernest H. Choy
    • Arthur F. Kavanaugh
    • Simon A. Jones
    Reviews
    Nature Reviews Rheumatology
    Volume: 9, P: 154-163

  • In 2016, two international organizations published recommendations for the management of psoriatic arthritis. This article reviews the development of the recommendations, considers their similarities and differences, and provides guidance on how to interpret and apply the recommendations in practice.

    • Laure Gossec
    • Laura C. Coates
    • Josef S. Smolen
    Reviews
    Nature Reviews Rheumatology
    Volume: 12, P: 743-750

  • Data from clinical trials of novel targeted therapies for psoriatic arthritis and other autoimmune diseases, which have produced sometimes surprising results, can inform our understanding of the immunopathogenesis of these diseases and help to identify the most relevant therapeutic targets.

    • Arlene Bravo
    • Arthur Kavanaugh
    Reviews
    Nature Reviews Rheumatology
    Volume: 15, P: 645-656

  • Rheumatoid arthritis is a chronic, inflammatory, autoimmune disease that primarily affects the joints. This Primer by Smolen et al. provides the latest insights into the epidemiology, genetics, pathophysiology, diagnostic approaches, clinical assessment and management of rheumatoid arthritis.

    • Josef S. Smolen
    • Daniel Aletaha
    • Kazuhiko Yamamoto
    Reviews
    Nature Reviews Disease Primers
    Volume: 4, P: 1-23

  • This Evidence-Based Guideline presents the latest treatment recommendations for medication selection in psoriatic arthritis (PsA), covering the six clinical domains of PsA, related conditions and associated comorbidities, and reflecting important advances in the field since the previous update.

    • Laura C. Coates
    • Enrique R. Soriano
    • Penelope Esther Palominos
    Reviews
    Nature Reviews Rheumatology
    Volume: 18, P: 465-479

  • Psoriatic arthritis (PsA) is a chronic immune-mediated form of arthritis that occurs in some patients with psoriasis. This Primer reviews the epidemiology and pathophysiology of PsA and highlights the challenges in diagnosis and advances in treatment. In addition, the authors discuss the quality of life of patients and outstanding questions in the field.

    • Oliver FitzGerald
    • Alexis Ogdie
    • Philip J. Mease
    Reviews
    Nature Reviews Disease Primers
    Volume: 7, P: 1-17